Theorem Clinical Research


Novo Nordisk, Takeda, Servier, Celgene among top sponsors rated by investigative sites in new CenterWatch survey

Monday, March 2, 2015 08:00 AM

More than 1,900 global investigative sites rate the best biopharmaceutical companies with which to work in a new survey conducted by CenterWatch, a leading provider of global clinical trials information. The survey results were released today in the March issue of The CenterWatch Monthly newsletter.

More... »

Quest Diagnostics

Janssen R&D launches three new research platforms

Friday, February 13, 2015 11:35 AM

Janssen R&D, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, has launched three new research platforms focused on disease prevention, disease interception and the microbiome—areas of transformational medical innovation that are expected to change the healthcare landscape. The new teams will collaborate closely with Janssen’s five therapeutic areas as well as external partners, to underpin ongoing research and propel scientific knowledge.

More... »

GlaxoSmithKline acquires GlycoVaxyn for $190M

Wednesday, February 11, 2015 12:32 PM

GlaxoSmithKline has acquired GlycoVaxyn, a specialist vaccine biopharmaceutical company based in Switzerland. Since forming a scientific collaboration in 2012, GSK has held a minority stake in GlycoVaxyn and now has acquired the remaining shares for $190 million in cash to take full ownership of the company.

More... »

NIHR, Janssen partner on rheumatoid arthritis biological treatments

Thursday, February 5, 2015 12:50 PM

A new clinical research study has been launched that will explore why the current gold standard biological treatment for people with rheumatoid arthritis does not work in around a third of patients. The National Institute for Health Research (NIHR) study in partnership with Janssen will investigate key mechanisms associated with a lack of response to this treatment and its findings should open new routes for developing therapies for these patients.

More... »

Johnson & Johnson forms Ebola vaccine development consortia

Monday, January 19, 2015 12:48 PM

Johnson & Johnson has formed a consortia with leading global research institutions and non-government organizations to work in conjunction with Janssen Pharmaceutical to accelerate the development of its Ebola vaccine regimen. The Innovative Medicines Initiative (IMI) plans to award these consortia grants totaling more than $116 million from the Ebola+ program to support the development, manufacturing and patient education for the vaccine regimen.

More... »

AC Immune, Janssen to collaborate on Alzheimer's disease vaccines

Friday, January 16, 2015 12:29 PM

AC Immune, a Swiss-based biopharmaceutical company, has entered into a worldwide exclusive license agreement and research collaboration with Janssen Pharmaceuticals to develop and commercialize therapeutic anti-Tau vaccines for the treatment of Alzheimer's disease and potentially other tauopathies.

More... »

35 partners from industry and academia collaborate on European research initiative

Thursday, January 15, 2015 01:40 PM

The European Prevention of Alzheimer's Dementia (EPAD) initiative has begun a novel collaboration between academic and private sectors to test innovative treatments for the prevention of Alzheimer’s dementia.

More... »

Vedanta Biosciences inks agreement with Janssen, Johnson & Johnson Innovation

Wednesday, January 14, 2015 12:29 PM

Vedanta Biosciences, a Boston-based microbiome company, has announced a license agreement with Janssen Biotech, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, for Vedanta's lead microbiome pharmaceutical candidate (VE202), which has demonstrated efficacy in published preclinical studies using models of autoimmune disease. The agreement was facilitated by the Johnson & Johnson Innovation Center in Boston.

More... »

X-Chem collaborates with Janssen and Johnson & Johnson Innovation

Monday, January 12, 2015 02:40 PM

X-Chem, a privately held biotechnology company based in Waltham, Mass., applying its drug discovery platform to the generation of novel small molecule therapeutics, has announced a multi-target collaboration with Janssen Biotech, one of the Janssen Pharmaceutical Companies of Johnson & Johnson.  The collaboration, which is being facilitated by Johnson & Johnson Innovation, Boston, focuses on the discovery and development of candidate molecules for the treatment of inflammatory diseases.

More... »

Johnson & Johnson begins phase I clinical trial of Ebola vaccine regimen

Thursday, January 8, 2015 02:19 PM

Johnson & Johnson has begun a phase I, first-in-human clinical trial of a preventive Ebola vaccine in development at its Janssen Pharmaceutical Companies. The trial is being led by the Oxford Vaccine Group, part of the University of Oxford Department of Pediatrics. Recruitment in the trial is underway, and the first volunteers have received their initial vaccine dose. Enrollment is expected to be completed by the end of January.

More... »


March 2

Huntingdon Life Sciences-Harlan prepares for rebranding and U.S. expansion to compete with early phase CROs Covance, CRL

Patients' increased sharing of clinical trial experiences through social media can help sponsors improve outcomes, enrollment

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly


Novo Nordisk, Takeda, Servier, Celgene among top sponsors
New gains seen from patient- and site-centric initiatives

Patient reported outcomes take center stage
FDA combining PROs, clinical outcomes in its approval decisions

Already a subscriber?
Log in to your digital subscription.

Purchase the March issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly


Study grants market breaks $13 billion
Volume of clinical activity rising while growth in grant spending slows

Revisiting eClinical Technology Solutions Adoption
While use of established solutions grows, sponsors hesitate on newer tools

Already a subscriber?
Log in to your digital subscription.

Purchase the February issue.

Subscribe to
The CenterWatch Monthly.


Featured Jobs